Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.64 |
| ▸ | ACHE | P22303 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | NQO2 | P16083 | 3/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748926 | 0.85 | MTNR1A (0.61) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL3223002 | 0.82 | MTNR1A (0.52) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL3752870 | 0.79 | ACHE (0.65) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL3854031 | 0.79 | MTNR1A (1.00) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL3751372 | 0.75 | MTNR1A (0.49) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL3975748 | 0.74 | MTNR1A (0.90) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL6523015 | 0.72 | MTNR1A (0.68) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL5526850 | 0.72 | MTNR1A (0.68) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL8765743 | 0.72 | MTNR1A (0.85) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL8765749 | 0.72 | MTNR1A (0.85) | MTNR1AMTNR1BACHECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298138-A1 | Aminoazoline and Urea Derivatives for Combating Animal Pests | BASF SE (DE) | 2010-11-25 | — | — | US | disclosed |
| EP-2120576-A2 | AMINOAZOLINE AND UREA DERIVATIVES FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008145615-A2 | AMINOAZOLINE AND UREA DERIVATIVES FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298138-A1 | Aminoazoline and Urea Derivatives for Combating Animal Pests | AADAT, INMT, SLC14A1 | MTNR1A 3214/4885MTNR1B 2479/4885ACHE 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.